The Aporia
The Straits Times. (2026, November 16). US FDA rejects closely watched lung cancer drug from China. The Straits Times. https://www.straitstimes.com/world/united-states/us-fda-rejects-closely-watched-lung-cancer-drug-from-china
The Straits Times. “US FDA rejects closely watched lung cancer drug from China.” The Straits Times, 16 Nov. 2026, https://www.straitstimes.com/world/united-states/us-fda-rejects-closely-watched-lung-cancer-drug-from-china.
The Straits Times. “US FDA rejects closely watched lung cancer drug from China.” The Straits Times, November 16, 2026. https://www.straitstimes.com/world/united-states/us-fda-rejects-closely-watched-lung-cancer-drug-from-china.
Dated from the outlet's own feed. Check the original for its byline.
The US Food and Drug Administration (FDA) rejected a groundbreaking lung cancer drug invented in China, dealing a significant blow to China’s ambitions in the global pharmaceutical industry. The drug, which was developed by Akeso Biopharma in China and licensed to Summit Therapeutics in Florida, was seen as a symbol of China’s growing prowess in drug development. Summit Therapeutics announced the FDA’s decision on November 15, 2026, marking a setback for the company’s efforts to bring the drug to the US market. The rejection highlights the rigorous standards set by the FDA and the challenges faced by international pharmaceutical companies in gaining approval in the United States.
a setback for a medicine that had become a symbol of China’s ascendance as a powerhouse in drug development